002422.SHE Sichuan Kelun Pharmaceutical Co Ltd
- Market cap
- CNY 65.1B
- P/E
- 33.0x
- P/B
- 2.46x
- ROE
- 7.5%
- Dividend yield
- 1.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002422.SHE undervalued?
Graham number002422.SHE trades 89.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sichuan Kelun Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Sichuan Kelun Pharmaceutical Co Ltd yet.
Sichuan Kelun Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the…
Full company profileSichuan Kelun Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sichuan Kelun Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.57B | 11.4B | 16.4B | 17.6B | 16.5B | 17.3B | 19.0B | 21.5B | 21.8B | 18.5B | 17.5B |
| Gross Profit | 3.63B | 5.79B | 9.67B | 10.6B | 8.60B | 9.28B | 9.95B | 11.2B | 11.2B | 8.86B | 8.29B |
| Operating Income | 653M | 1.16B | 1.36B | 1.28B | 1.01B | 1.32B | 2.20B | 3.65B | 4.43B | 2.49B | 1.77B |
| EBITDA | 1.65B | 1.93B | 2.82B | 2.77B | 2.38B | 2.69B | 3.42B | 4.60B | 5.25B | 3.91B | 2.73B |
| Net Income | 585M | 749M | 1.21B | 938M | 829M | 1.10B | 1.71B | 2.46B | 2.94B | 1.70B | 1.96B |
| EPS | 0.41 | 0.52 | 0.85 | 0.66 | 0.58 | 0.78 | 1.15 | 1.59 | 1.86 | 1.07 | 1.23 |
| Balance Sheet | |||||||||||
| Total Assets | 23.4B | 28.0B | 29.3B | 31.5B | 32.0B | 31.5B | 34.2B | 36.5B | 37.3B | 39.8B | 43.0B |
| Total Liabilities | 11.9B | 16.0B | 16.4B | 17.6B | 18.0B | 17.4B | 17.3B | 13.4B | 10.6B | 10.5B | 10.7B |
| Shareholders' Equity | 11.3B | 11.8B | 12.7B | 13.2B | 13.5B | 13.9B | 15.7B | 19.7B | 22.5B | 24.2B | 26.0B |
| Cash & Short-term Investments | 1.35B | 1.74B | 2.03B | 2.25B | 3.04B | 3.28B | 5.18B | 6.37B | 5.90B | 6.03B | 7.03B |
| Total Debt | 4.21B | 6.22B | 8.10B | 5.32B | 9.38B | 6.89B | 8.05B | 6.35B | 3.34B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.73B | 1.20B | 2.95B | 2.22B | 2.22B | 2.85B | 3.13B | 5.34B | 4.49B | 2.64B | - |
| Capital Expenditure | 1.37B | 1.48B | 1.33B | 1.33B | 1.23B | 991M | 896M | 1.77B | 1.68B | 1.62B | 1.25B |
| Free Cash Flow | 356M | -375M | 1.62B | 886M | 988M | 1.86B | 2.23B | 3.57B | 2.81B | 1.02B | 2.39B |
| Ratios | |||||||||||
| ROE | 5.2% | 6.3% | 9.5% | 7.1% | 6.1% | 8.0% | 10.8% | 12.5% | 13.1% | 7.0% | 7.5% |
| ROA | 2.5% | 2.7% | 4.1% | 3.0% | 2.6% | 3.5% | 5.0% | 6.7% | 7.9% | 4.3% | 4.5% |
| Net Profit Margin | 6.8% | 6.5% | 7.4% | 5.3% | 5.0% | 6.4% | 9.0% | 11.4% | 13.5% | 9.2% | 11.2% |
| Debt to Equity | 0.37x | 0.53x | 0.64x | 0.40x | 0.69x | 0.50x | 0.51x | 0.32x | 0.15x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sichuan Kelun Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.68%
- Forward dividend
- 0.59 CNY
- Payout ratio
- 64.1%
- Ex-dividend date
- Oct 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.09B | 0.68 | 64.1% |
| 2024 | CNY 1.81B | 1.15 | 61.7% |
| 2023 | CNY 1.13B | 0.73 | 45.9% |
| 2022 | CNY 598M | 0.40 | 35.1% |
| 2021 | CNY 450M | 0.32 | 40.8% |
| 2020 | CNY 602M | 0.42 | 72.6% |
| 2019 | CNY 300M | 0.21 | 32.0% |
| 2018 | CNY 984M | 0.69 | 81.1% |
| 2017 | CNY 647M | 0.45 | 86.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jul 22, 2015.
Who owns Sichuan Kelun Pharmaceutical Co Ltd
- Insiders 33.15%
- Institutions 16.45%
- Public & others 50.40%
- Shares outstanding 1.59B
- Free float 1.09B
Sichuan Kelun Pharmaceutical Co Ltd company profile
- Company name
- Sichuan Kelun Pharmaceutical Co Ltd
- Ticker
- 002422.SHE
- ISIN
- CNE100000PW7
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 3, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 20,127
- Fiscal year end
- December
- Address
- No.36 Baihua West Road, Chengdu, China, 610071
- Phone
- 86 40 0686 0333
- Website
- kelun.com
About Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Sichuan Kelun Pharmaceutical Co Ltd management
8- Mr. Sichuan LiuGM & Director · born 1984
- Mr. Degui LaiCFO & Deputy GM · born 1971
- Mr. Hao FengDeputy GM & Secretary of the Board of Directors · born 1980
- Mr. Zhonghua WuDeputy General Manager · born 1968
- Ms. Yihong LiaoDeputy General Manager · born 1979
- Lanlan LiSales Manager
- Mr. Yi FengDeputy GM & Chief Strategy Officer · born 1966
- Mr. Deguang ChenOfficer · born 1971